NCT00017745

Brief Summary

The Neuromuscular Diseases Section (NDS) is conducting research on certain inherited myopathies and neuropathies, disorders that lead to disability and sometimes death. NDS, along with other groups, has identified some disease-causing genes. The National Institutes of Health Clinical Center proposes new research to identify additional hereditary neuromuscular diseases and conduct genetic studies in order to localize, clone, and characterize the diseases. An expected 50 patients with known or suspected inherited myopathy or neuropathy and their families will be recruited for this study. If travel to the Clinical Center is impossible, investigators may come to them to do the tests. Ten to twenty cubic centimeters of blood will be drawn for DNA extraction and genotyping. Some abnormal movements of muscle atrophy will be documented by videotaping. If necessary, diagnostic laboratory and radiographic studies will be done to confirm diagnosis. Because the diseases are hereditary, blood may also be drawn from family members. The family will be counseled and the participants invited back annually to investigate the progression of the disease. Each participant will be evaluated by a history and initial neurological exam. Up to another 20 mL of blood will be drawn for routine blood studies. Other medical care procedures may include a chest x-ray, EKG and echocardiogram, CT (computed tomography) or MRI (magnetic resonance imaging) scan, pulmonary function tests, and physical therapy assessment. Possible research procedures may include MR spectroscopy, nerve conduction study, electromyography, muscle or nerve biopsy, and lumbar puncture. The researchers have decided not to inform the family if nonpaternity or adoption is discovered by the DNA genotyping. Also, because a carrier of the disease gene may not necessarily develop the disease, family members will not be informed if they are carriers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2001

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2001

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

June 8, 2001

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 11, 2001

Completed
5.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 10, 2007

Completed
Last Updated

July 2, 2017

Status Verified

May 10, 2007

First QC Date

June 8, 2001

Last Update Submit

June 30, 2017

Conditions

Keywords

DNAHereditary MyopathiesIntermediate FilamentsCardiomyopathiesGenetic TestingMyopathyInherited Neuromuscular Disorder

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of all ages with known or suspected inherited myopathies or neuropathies or neuropathies and their families will be considered as potential candidates for the study.
  • Pregnant women will be included.
  • Family members of studied patients who express interest in participating will be also accepted.
  • Willingness and legal ability to give and sign informed study consent.
  • Willingness to travel to the Clinical Center for evaluation if necessary.
  • Willingness to submit tissue for testing this may include muscle, nerve and peripheral blood.

You may not qualify if:

  • People with no known or suspected inherited myopathies or neuropathies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

  • Sivakumar K, Cervenakova L, Dalakas MC, Leon-Monzon M, Isaacson SH, Nagle JW, Vasconcelos O, Goldfarb LG. Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. Ann Neurol. 1995 Aug;38(2):267-9. doi: 10.1002/ana.410380222.

    PMID: 7654077BACKGROUND

MeSH Terms

Conditions

Neuromuscular DiseasesCardiomyopathiesMuscular Diseases

Condition Hierarchy (Ancestors)

Nervous System DiseasesHeart DiseasesCardiovascular DiseasesMusculoskeletal Diseases

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

June 8, 2001

First Posted

June 11, 2001

Study Start

June 1, 2001

Study Completion

May 10, 2007

Last Updated

July 2, 2017

Record last verified: 2007-05-10

Locations